Keybanc Maintains Overweight on Certara, Raises Price Target to $12

10/16/2026
Impact: 70
Healthcare

Keybanc analyst Scott Schoenhaus has maintained an Overweight rating on Certara (NASDAQ: CERT) and raised the price target from $9 to $12. This adjustment reflects a positive outlook on the company's performance.

AI summary, not financial advice

Share: